Non-Small Cell Lung Cancer

CROSS-DISEASE TRIALS:

- **IRB# 18094**: S1609 (DART)
- **IRB# 19992**: MATCH
- **IRB# 21325**: RGX-104

**1st line**

**Squamous**

- **IRB# 21821 CodeBreak 101**: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

**2nd/3rd Line**

**Squamous**

- **IRB# 22874**: Iovance TIL
  A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

**Non-squamous**

- **IRB# 23575 NIT-119**: A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

- **IRB# 21821 CodeBreak 101**: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetic, and Efficacy of AMG 510 (INN Sotorasib) in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)

- **IRB# 23575 NIT-119**: A multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 (efineptakin alfa) in combination with atezolizumab in subjects with previously untreated, PD-L1-expressing, locally advanced or metastatic Non-Small Cell Lung Cancer

**Non-squamous**

- **IRB# 23856 ORCHARD**: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small-Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)

**KEY**

- Open to Enrollment
- In Development
- Enrollment on Hold

14 FEB 2022

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result